Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer

被引：0
|
作者：
Luck, HJ
Thomssen, C
duBois, A
Lisboa, BW
Untch, M
Kuhnle, H
Janicke, F
Meerpohl, HG
Lindner, C
Kcnecny, G
Hecker, D
Diergarten, K
机构：
[1] UNIV MUNICH,MUNICH,GERMANY
[2] ST VINCENTIUS KRANKENHAUSER,FRAUENKLIN,KARLSRUHE,GERMANY
[3] UNIV HAMBURG,FRAUENKLIN EPPENDORF,HAMBURG,GERMANY
[4] UNIV MUNICH,KLINIKUM GROSSHADERN,D-8000 MUNICH,GERMANY
[5] BRISTOL MYERS SQUIBB CO,MUNICH,GERMANY
来源：
SEMINARS IN ONCOLOGY | 1997年 / 24卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S16
页数：4
相关论文
共 50 条
  • [41] Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
    Gennari, A
    Bruzzi, P
    Orlandini, C
    Salvadori, B
    Donati, S
    Landucci, E
    Guarneri, V
    Rondini, M
    Ricci, S
    Conte, P
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 962 - 967
  • [42] Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
    A Gennari
    P Bruzzi
    C Orlandini
    B Salvadori
    S Donati
    E Landucci
    V Guarneri
    M Rondini
    S Ricci
    P Conte
    [J]. British Journal of Cancer, 2004, 90 : 962 - 967
  • [43] Randomized phase II study of docetaxel vs. epirubicin/cyclophosphamide to optimize first-line therapy of metastatic breast cancer (MBC): preliminary results of the TIPP study.
    Wasemann, C
    Di Liberto, A
    Ertan, K
    Schmidt, W
    Friedrich, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S89 - S89
  • [44] Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
    Blum, Joanne L.
    Dees, E. Claire
    Chacko, Aparna
    Doane, Lisa
    Ethirajan, Sukumar
    Hopkins, Judith
    McMahon, Richard
    Merten, Suzan
    Negron, Angel
    Neubauer, Marcus
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4384 - 4390
  • [45] Weekly paclitaxel, doxorubicin, and carboplatin in the first-line treatment of patients with metastatic breast cancer
    Hainsworth, JD
    Burris, HA
    Greco, FA
    [J]. SEMINARS IN ONCOLOGY, 1999, 26 (06) : 13 - 13
  • [46] Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
    Gamucci, T.
    D'Ottavio, A. M.
    Magnolfi, E.
    Barduagni, M.
    Vaccaro, A.
    Sperduti, I.
    Moscetti, L.
    Belli, F.
    Meliffi, L.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1040 - 1045
  • [47] Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer
    Kevin R. Fox
    [J]. Current Oncology Reports, 2009, 11 : 5 - 7
  • [48] Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer
    Baltali, E
    Altundag, MK
    Güler, N
    Özisik, Y
    Firat, D
    Baran, I
    Tekuzman, G
    [J]. TUMORI, 2002, 88 (03) : 200 - 203
  • [49] Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
    T Gamucci
    A M D'Ottavio
    E Magnolfi
    M Barduagni
    A Vaccaro
    I Sperduti
    L Moscetti
    F Belli
    L Meliffi
    [J]. British Journal of Cancer, 2007, 97 : 1040 - 1045
  • [50] Adding Bevacizumab to Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer
    Fox, Kevin R.
    [J]. CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 5 - 6
12345